Your browser doesn't support javascript.
loading
Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
Meister, Michael T; Voss, Sandra; Schwabe, Dirk.
Afiliação
  • Meister MT; Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
  • Voss S; Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
  • Schwabe D; Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
Pediatr Blood Cancer ; 62(11): 2018-20, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26109475
ABSTRACT
Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia Telangiectasia / Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Herpesvirus Humano 4 / Imunoconjugados / Infecções por Vírus Epstein-Barr / Rituximab Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia Telangiectasia / Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Herpesvirus Humano 4 / Imunoconjugados / Infecções por Vírus Epstein-Barr / Rituximab Idioma: En Ano de publicação: 2015 Tipo de documento: Article